The Use of Valrubicin for the Chemoresection of Superficial Bladder Cancer – A Marker Lesion Study
Objectives: To assess the effect and tolerance of a 6–week course of intravesical valrubicin on a tumour intentionally left in the bladder (marker lesion) following incomplete transurethral resection of the bladder (TURBT). Patients and Methods: In a prospective phase II study, 40 patients with refr...
Gespeichert in:
| Veröffentlicht in: | European urology 2001-06, Vol.39 (6), p.643-647 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 647 |
|---|---|
| container_issue | 6 |
| container_start_page | 643 |
| container_title | European urology |
| container_volume | 39 |
| creator | Newling, D.W.W. Hetherington, J. Sundaram, S.K. Robinson, M.R.G. Kisbenedek, L. |
| description | Objectives: To assess the effect and tolerance of a 6–week course of intravesical valrubicin on a tumour intentionally left in the bladder (marker lesion) following incomplete transurethral resection of the bladder (TURBT). Patients and Methods: In a prospective phase II study, 40 patients with refractory superficial transitional cell carcinoma (TCC), with or without carcinoma in situ, underwent TURBT at which a tumour |
| doi_str_mv | 10.1159/000052521 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_11464052</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71029538</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-4e8203b976976f46a7650b13f8b916969f792ed1013d1d8b7a0db3d9f4ceb5cb3</originalsourceid><addsrcrecordid>eNpt0MtKAzEUBuAgitbLwrUgQURwMZpMJpnJUos3qAi2dTvkcqKj005NZhbufAff0CcxtUVdGAIhnO-chB-hXUpOKOXylMTFU57SFdSjRc6SnAuyinqEkTRJC1ZsoM0QnqNiXLJ1tEFpJrLY0kN29AR4HAA3Dj-o2ne6MtUUu8bjNlb6TzBpPAQwbdVM52jYzcC7iFSNz2tlLXjcV1MTj8_3D3yGb5V_iZcBhHnHsO3s2zZac6oOsLM8t9D48mLUv04Gd1c3_bNBYhjP2ySDIiVMy1zE7TKhcsGJpswVWlIhhXS5TMFSQpmlttC5IlYzK11mQHOj2RY6Wsyd-ea1g9CWkyoYqGs1haYLZU5JKjkrIjxeQOObEDy4cuarifJvJSXlPNLyJ9Jo95dDOz0B-yuXGUZwuAQqGFU7H9Oowp-JohBkzg4W7EX5R_A_9Yvx_fdD5cy6iPb-RYuvfAG4N5GH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71029538</pqid></control><display><type>article</type><title>The Use of Valrubicin for the Chemoresection of Superficial Bladder Cancer – A Marker Lesion Study</title><source>MEDLINE</source><source>Karger Journals</source><creator>Newling, D.W.W. ; Hetherington, J. ; Sundaram, S.K. ; Robinson, M.R.G. ; Kisbenedek, L.</creator><creatorcontrib>Newling, D.W.W. ; Hetherington, J. ; Sundaram, S.K. ; Robinson, M.R.G. ; Kisbenedek, L.</creatorcontrib><description>Objectives: To assess the effect and tolerance of a 6–week course of intravesical valrubicin on a tumour intentionally left in the bladder (marker lesion) following incomplete transurethral resection of the bladder (TURBT). Patients and Methods: In a prospective phase II study, 40 patients with refractory superficial transitional cell carcinoma (TCC), with or without carcinoma in situ, underwent TURBT at which a tumour <1 cm in diameter was deliberately left in the bladder. They were then treated with six instillations of 800 mg valrubicin at weekly intervals. Patients were assessed three months after the initial TURBT by cystoscopy and biopsy. Patients remaining clear of disease underwent repeat cystoscopies at 3–monthly intervals until recurrence or for up 2 years. Results: 21/39 (54%) of patients were found to be clinically clear of disease upon cystoscopic examination at 3 months. 18/39 (46%) of patients were considered histologically clear of bladder disease. The current estimate of the mean time to recurrence is 248 days. Conclusions:A 6–week course of intravesical valrubicin has proved effective in ablating a marker tumour left in the bladder after incomplete TURBT and in preventing or delaying recurrence of further tumours in a group of patients with previously treated superficial TCC.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>EISSN: 1421-993X</identifier><identifier>DOI: 10.1159/000052521</identifier><identifier>PMID: 11464052</identifier><identifier>CODEN: EUURAV</identifier><language>eng</language><publisher>Basel, Switzerland: Elsevier</publisher><subject>Administration, Intravesical ; Aged ; Biological and medical sciences ; Bladder and Urothelial Cancer ; Carcinoma, Transitional Cell - drug therapy ; Carcinoma, Transitional Cell - pathology ; Carcinoma, Transitional Cell - surgery ; Doxorubicin - administration & dosage ; Doxorubicin - analogs & derivatives ; Doxorubicin - therapeutic use ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - surgery ; Nephrology. Urinary tract diseases ; Prospective Studies ; Time Factors ; Tumors of the urinary system ; Urinary Bladder - drug effects ; Urinary Bladder - pathology ; Urinary Bladder - surgery ; Urinary Bladder Neoplasms - drug therapy ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - surgery ; Urinary tract. Prostate gland</subject><ispartof>European urology, 2001-06, Vol.39 (6), p.643-647</ispartof><rights>2001 S. Karger AG, Basel</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-4e8203b976976f46a7650b13f8b916969f792ed1013d1d8b7a0db3d9f4ceb5cb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1068602$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11464052$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Newling, D.W.W.</creatorcontrib><creatorcontrib>Hetherington, J.</creatorcontrib><creatorcontrib>Sundaram, S.K.</creatorcontrib><creatorcontrib>Robinson, M.R.G.</creatorcontrib><creatorcontrib>Kisbenedek, L.</creatorcontrib><title>The Use of Valrubicin for the Chemoresection of Superficial Bladder Cancer – A Marker Lesion Study</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Objectives: To assess the effect and tolerance of a 6–week course of intravesical valrubicin on a tumour intentionally left in the bladder (marker lesion) following incomplete transurethral resection of the bladder (TURBT). Patients and Methods: In a prospective phase II study, 40 patients with refractory superficial transitional cell carcinoma (TCC), with or without carcinoma in situ, underwent TURBT at which a tumour <1 cm in diameter was deliberately left in the bladder. They were then treated with six instillations of 800 mg valrubicin at weekly intervals. Patients were assessed three months after the initial TURBT by cystoscopy and biopsy. Patients remaining clear of disease underwent repeat cystoscopies at 3–monthly intervals until recurrence or for up 2 years. Results: 21/39 (54%) of patients were found to be clinically clear of disease upon cystoscopic examination at 3 months. 18/39 (46%) of patients were considered histologically clear of bladder disease. The current estimate of the mean time to recurrence is 248 days. Conclusions:A 6–week course of intravesical valrubicin has proved effective in ablating a marker tumour left in the bladder after incomplete TURBT and in preventing or delaying recurrence of further tumours in a group of patients with previously treated superficial TCC.</description><subject>Administration, Intravesical</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Bladder and Urothelial Cancer</subject><subject>Carcinoma, Transitional Cell - drug therapy</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Carcinoma, Transitional Cell - surgery</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - analogs & derivatives</subject><subject>Doxorubicin - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prospective Studies</subject><subject>Time Factors</subject><subject>Tumors of the urinary system</subject><subject>Urinary Bladder - drug effects</subject><subject>Urinary Bladder - pathology</subject><subject>Urinary Bladder - surgery</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - surgery</subject><subject>Urinary tract. Prostate gland</subject><issn>0302-2838</issn><issn>1873-7560</issn><issn>1421-993X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0MtKAzEUBuAgitbLwrUgQURwMZpMJpnJUos3qAi2dTvkcqKj005NZhbufAff0CcxtUVdGAIhnO-chB-hXUpOKOXylMTFU57SFdSjRc6SnAuyinqEkTRJC1ZsoM0QnqNiXLJ1tEFpJrLY0kN29AR4HAA3Dj-o2ne6MtUUu8bjNlb6TzBpPAQwbdVM52jYzcC7iFSNz2tlLXjcV1MTj8_3D3yGb5V_iZcBhHnHsO3s2zZac6oOsLM8t9D48mLUv04Gd1c3_bNBYhjP2ySDIiVMy1zE7TKhcsGJpswVWlIhhXS5TMFSQpmlttC5IlYzK11mQHOj2RY6Wsyd-ea1g9CWkyoYqGs1haYLZU5JKjkrIjxeQOObEDy4cuarifJvJSXlPNLyJ9Jo95dDOz0B-yuXGUZwuAQqGFU7H9Oowp-JohBkzg4W7EX5R_A_9Yvx_fdD5cy6iPb-RYuvfAG4N5GH</recordid><startdate>20010601</startdate><enddate>20010601</enddate><creator>Newling, D.W.W.</creator><creator>Hetherington, J.</creator><creator>Sundaram, S.K.</creator><creator>Robinson, M.R.G.</creator><creator>Kisbenedek, L.</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010601</creationdate><title>The Use of Valrubicin for the Chemoresection of Superficial Bladder Cancer – A Marker Lesion Study</title><author>Newling, D.W.W. ; Hetherington, J. ; Sundaram, S.K. ; Robinson, M.R.G. ; Kisbenedek, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-4e8203b976976f46a7650b13f8b916969f792ed1013d1d8b7a0db3d9f4ceb5cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Administration, Intravesical</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Bladder and Urothelial Cancer</topic><topic>Carcinoma, Transitional Cell - drug therapy</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Carcinoma, Transitional Cell - surgery</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - analogs & derivatives</topic><topic>Doxorubicin - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prospective Studies</topic><topic>Time Factors</topic><topic>Tumors of the urinary system</topic><topic>Urinary Bladder - drug effects</topic><topic>Urinary Bladder - pathology</topic><topic>Urinary Bladder - surgery</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - surgery</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Newling, D.W.W.</creatorcontrib><creatorcontrib>Hetherington, J.</creatorcontrib><creatorcontrib>Sundaram, S.K.</creatorcontrib><creatorcontrib>Robinson, M.R.G.</creatorcontrib><creatorcontrib>Kisbenedek, L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Newling, D.W.W.</au><au>Hetherington, J.</au><au>Sundaram, S.K.</au><au>Robinson, M.R.G.</au><au>Kisbenedek, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Use of Valrubicin for the Chemoresection of Superficial Bladder Cancer – A Marker Lesion Study</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2001-06-01</date><risdate>2001</risdate><volume>39</volume><issue>6</issue><spage>643</spage><epage>647</epage><pages>643-647</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><eissn>1421-993X</eissn><coden>EUURAV</coden><abstract>Objectives: To assess the effect and tolerance of a 6–week course of intravesical valrubicin on a tumour intentionally left in the bladder (marker lesion) following incomplete transurethral resection of the bladder (TURBT). Patients and Methods: In a prospective phase II study, 40 patients with refractory superficial transitional cell carcinoma (TCC), with or without carcinoma in situ, underwent TURBT at which a tumour <1 cm in diameter was deliberately left in the bladder. They were then treated with six instillations of 800 mg valrubicin at weekly intervals. Patients were assessed three months after the initial TURBT by cystoscopy and biopsy. Patients remaining clear of disease underwent repeat cystoscopies at 3–monthly intervals until recurrence or for up 2 years. Results: 21/39 (54%) of patients were found to be clinically clear of disease upon cystoscopic examination at 3 months. 18/39 (46%) of patients were considered histologically clear of bladder disease. The current estimate of the mean time to recurrence is 248 days. Conclusions:A 6–week course of intravesical valrubicin has proved effective in ablating a marker tumour left in the bladder after incomplete TURBT and in preventing or delaying recurrence of further tumours in a group of patients with previously treated superficial TCC.</abstract><cop>Basel, Switzerland</cop><pub>Elsevier</pub><pmid>11464052</pmid><doi>10.1159/000052521</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0302-2838 |
| ispartof | European urology, 2001-06, Vol.39 (6), p.643-647 |
| issn | 0302-2838 1873-7560 1421-993X |
| language | eng |
| recordid | cdi_pubmed_primary_11464052 |
| source | MEDLINE; Karger Journals |
| subjects | Administration, Intravesical Aged Biological and medical sciences Bladder and Urothelial Cancer Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology Carcinoma, Transitional Cell - surgery Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Doxorubicin - therapeutic use Female Humans Male Medical sciences Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - surgery Nephrology. Urinary tract diseases Prospective Studies Time Factors Tumors of the urinary system Urinary Bladder - drug effects Urinary Bladder - pathology Urinary Bladder - surgery Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - surgery Urinary tract. Prostate gland |
| title | The Use of Valrubicin for the Chemoresection of Superficial Bladder Cancer – A Marker Lesion Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A43%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Use%20of%20Valrubicin%20for%20the%20Chemoresection%20of%20Superficial%20Bladder%20Cancer%20%E2%80%93%20A%20Marker%20Lesion%20Study&rft.jtitle=European%20urology&rft.au=Newling,%20D.W.W.&rft.date=2001-06-01&rft.volume=39&rft.issue=6&rft.spage=643&rft.epage=647&rft.pages=643-647&rft.issn=0302-2838&rft.eissn=1873-7560&rft.coden=EUURAV&rft_id=info:doi/10.1159/000052521&rft_dat=%3Cproquest_pubme%3E71029538%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71029538&rft_id=info:pmid/11464052&rfr_iscdi=true |